Premium
SCAR : The high‐prevalence antigen 013.008 in the Scianna blood group system
Author(s) -
Srivastava Kshitij,
Albasri Jasem,
Alsuhaibani Omar M.,
Aljasem Hassan A.,
Bueno Marina U.,
Antonacci Tania,
Branch Donald R.,
Denomme Gregory A.,
Flegel Willy A.
Publication year - 2021
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.16152
Subject(s) - hemolysis , antigen , antibody , titer , allele , recombinant dna , rh blood group system , immunology , antibody titer , medicine , blood transfusion , microbiology and biotechnology , biology , gene , genetics
Background The Scianna (SC) blood group system comprises seven antigens. They reside on the erythroblast membrane‐associated glycoprotein (ERMAP). The ERMAP and RHCE genes are juxtaposed to each other on chromosome 1. We report a novel SC antigen. Study Design and Methods Blood samples came from a patient and his two sisters in Saudi Arabia. To investigate the antibody specificity we used the column agglutination technique and soluble recombinant ERMAP protein. The significance of anti‐SCAR was evaluated by the transfusion history and a monocyte monolayer assay. We determined the genomic sequence of ERMAP and RHCE genes. Results The patientʼs serum showed an antibody of titer 8 against a high‐prevalence antigen. The soluble recombinant ERMAP protein inhibited the antibody. The propositus genotyped homozygous for an ERMAP:c.424C>G variant, for which his sisters were heterozygous. The c.424C>G variant occurred in the SC*01 allele in one haplotype with the RHCE*03 ( RHCE*cE ) allele. No signs of hemolysis occurred following an incompatible blood transfusion. The monocyte monolayer assay was negative. Conclusions We characterized a high‐prevalence antigen, with the proposed name “SCAR,” which is the eighth antigen of the Scianna blood group system (proposed designation 013.008). Individuals homozygous for ERMAP:p.(Gln142Glu) protein variant can produce anti‐SCAR. Although we did not observe any sign of hemolysis at this time, the anti‐SCAR prompted a change of the treatment regimen. A review of the known reports indicated that all SC alloantibodies of sufficient titer should be considered capable of causing hemolysis.